RLF Stock Overview
Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Relief Therapeutics Holding SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF1.38 |
52 Week High | CHF15.00 |
52 Week Low | CHF1.30 |
Beta | -14.37 |
1 Month Change | -13.75% |
3 Month Change | -25.41% |
1 Year Change | -82.03% |
3 Year Change | -98.85% |
5 Year Change | -38.39% |
Change since IPO | -93.10% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?
May 05Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?
Oct 04Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?
Apr 23Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?
Sep 25We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide
Jan 13Shareholder Returns
RLF | CH Biotechs | CH Market | |
---|---|---|---|
7D | 3.6% | 16.4% | 0.9% |
1Y | -82.0% | -1.1% | 4.2% |
Return vs Industry: RLF underperformed the Swiss Biotechs industry which returned -5.7% over the past year.
Return vs Market: RLF underperformed the Swiss Market which returned 4.3% over the past year.
Price Volatility
RLF volatility | |
---|---|
RLF Average Weekly Movement | 6.4% |
Biotechs Industry Average Movement | 7.4% |
Market Average Movement | 3.4% |
10% most volatile stocks in CH Market | 7.7% |
10% least volatile stocks in CH Market | 1.8% |
Stable Share Price: RLF's share price has been volatile over the past 3 months.
Volatility Over Time: RLF's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 69 | Michelle Lock | https://www.relieftherapeutics.com |
Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.
Relief Therapeutics Holding SA Fundamentals Summary
RLF fundamental statistics | |
---|---|
Market cap | CHF17.31m |
Earnings (TTM) | -CHF80.79m |
Revenue (TTM) | CHF5.86m |
3.0x
P/S Ratio-0.2x
P/E RatioIs RLF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RLF income statement (TTM) | |
---|---|
Revenue | CHF5.86m |
Cost of Revenue | CHF1.45m |
Gross Profit | CHF4.41m |
Other Expenses | CHF85.20m |
Earnings | -CHF80.79m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -6.44 |
Gross Margin | 75.26% |
Net Profit Margin | -1,378.18% |
Debt/Equity Ratio | 1.8% |
How did RLF perform over the long term?
See historical performance and comparison